Chai Discovery, a startup building AI models that predict and redesign molecular interactions, has raised $400 million in a Series C funding round that values the company at $3.8 billion — nearly triple the $1.3 billion valuation it carried just seven months earlier. The round was led by Index Ventures, with participation from Kleiner Perkins, Sequoia Capital and Dimension, and brings Chai’s total funding to roughly $630 million, including a $130 million round at the earlier $1.3 billion valuation in December.
From Academic Tool to Pharma Partner
Chai Discovery’s platform generates novel molecular designs, including antibodies, by modeling protein structures and interactions computationally rather than relying solely on traditional wet-lab screening. The company says its technology is now in active use by Eli Lilly and Pfizer to pursue drug targets both companies had previously considered difficult or effectively inaccessible using conventional discovery methods — a claim that, if borne out in clinical results, would mark one of the more concrete pharma validations of AI-designed biologics to date, and a notable escalation from the smaller biotech partnerships that characterized the sector just a year earlier.
Chai-3 and the Race for Better Binding Affinity
The company’s latest model, Chai-3, is built to improve on its predecessor specifically on two metrics that matter most to drug developers: target success rates and binding affinity, the strength with which a designed molecule attaches to its intended target in the body. Stronger binding affinity generally translates into lower required doses and fewer off-target side effects, which is why pharmaceutical partners have focused their earliest validation efforts on that metric rather than broader claims about AI “designing drugs” wholesale. Company engineers say Chai-3’s improvements come primarily from training on a larger library of experimentally validated protein structures rather than from a fundamentally new model architecture.
A Sector Still Waiting for Its First Approval
Chai’s fundraising surge comes against a sobering industry backdrop: as of October 2026, no drug discovered or designed by artificial intelligence has received full approval from the U.S. Food and Drug Administration. AI-discovered compounds have experienced Phase 2 trial failure rates roughly comparable to traditionally discovered drugs, undercutting the industry’s early marketing narrative that AI would dramatically outperform conventional discovery on success rates alone, a gap between promise and proof that has become a recurring talking point among biotech skeptics.
The Skeptics: Valuation Ahead of Validation
That gap between soaring valuations and the absence of regulatory approvals has drawn pointed criticism from biotech investors who argue the sector is pricing in success years before clinical data can confirm it. Rivals in the space, including Google DeepMind’s spinout Isomorphic Labs, which closed a $2.1 billion round in May, face the same scrutiny: large sums raised against the promise of AI-designed therapeutics, with full Phase 3 results for any AI-originated drug still pending across the industry. Some venture investors outside the Chai deal have openly questioned whether a tripled valuation in seven months reflects genuine technical progress or simply capital chasing a hot sector narrative.
The Bull Case From Investors
Chai’s backers counter that drug development timelines are inherently long — typically a decade or more from discovery to approval — and that judging an AI drug-discovery platform’s value by whether it has already produced an approved drug misunderstands where the technology sits in that cycle. Index Ventures and its co-investors are betting that partnerships with large pharmaceutical companies like Lilly and Pfizer, rather than early valuation multiples, are the more meaningful signal of whether Chai’s molecular designs will eventually translate into marketed therapies.
What’s Next
The next concrete milestone to watch is whether any Chai-designed antibody advances into human clinical trials under its pharma partners, which would mark the first real-world test of whether its computational designs perform as predicted in patients rather than in silico. Until then, Chai’s tripled valuation remains a bet on potential rather than proof — one shared by nearly every company in the fast-growing AI drug-design sector, and one that investors across the space acknowledge could unwind quickly if an early high-profile trial disappoints. Company executives have said they expect to disclose which specific targets have progressed furthest within its pharma partnerships in the coming months, a disclosure that would give outside observers their first real benchmark for judging the platform’s clinical progress rather than relying on funding announcements alone.
Photo: Edward Jenner / PEXELS via Pexels
